Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., Feb. 3, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.
Credit: Khademhosseini Lab
(LOS ANGELES) - There are many mechanisms by which the body responds to foreign invaders. One of these involves the T-cells of the immune system, which have a number of different proteins on their surface called checkpoint proteins. These checkpoint proteins bind to proteins on the surface of other cells and can result in either stimulation or suppression of T-cell activity. Normally, surface proteins on foreign or invading cells will produce a stimulation of T-cell activity against these cells, while T-cell suppression is a built-in mechanism to prevent the immune system from attacking the body s own normal cells.
Researchers at the Brigham and Womenâs Hospital in Boston said in a 2014 report that medical science âroutinely failsâ to include women in clinical trials and at all stages of medical research. A 2016 report in Pharmacy Practice cited evidence that historically medicine has failed to adequately enrol women in scientific studies and these deficiencies âhave hindered the progress of understanding womenâs response to medicationsâ.
Until just 25 years ago, all women of reproductive age were routinely excluded from medical studies, with scientists assuming the results of testing on menâs bodies would apply equally to women.
And so this story comes back to one that we have heard more and more about recently, but not in the context of vaccine hesitancy: we simply donât know enough about how womenâs bodies work.
Epidemiology of soil-transmitted helminth infections in Semarang, Central Java, Indonesia
Johanna Kurscheid ,
Affiliation Yayasan Wahana Bakti Sejatera Foundation (YWBS), Semarang, Indonesia ⨯
M. J. Park,
Affiliation Department of Nursing, College of Nursing, Konyang University, Daejeon, South Korea
Affiliation Faculty of Health Sciences, Curtin University, Bentley, Australia ⨯
Ross Sadler,
Affiliation School of Public Health, Griffith Health, Griffith University, South Brisbane, Australia ⨯
James S. McCarthy,
Affiliation QIMR Berghofer Medical Research Institute, Herston, Australia ⨯
Susana V. Nery,
Affiliation Public Health Interventions Group, Kirby Institute, University of New South Wales, Kensington, Australia ⨯
Ricardo Soares-Magalhaes,
Affiliation School of Veterinary Science, University of Queensland, Brisbane, Australia
Affiliation
MedCity News
Innovative payment models to support cell and gene therapies on the rise (video)
As precision medicine gains steam, the question arises: how can reimbursement models evolve to support these often costly therapies and ensure patient access is not blocked? Drugmakers and payers are working together to find some answers.
Shares1
As the precision medicine field evolves and the science behind personalized therapies for complex conditions surges ahead, reimbursement models are racing to catch up. Precision medicine treatments, like cell and gene therapies, tend to have high price tags and novel delivery mechanisms. This makes creating effective payment models for these therapies a challenge, but drug developers and payers are working together to create out-of-the-box solutions.